Bupropion in the treatment of depression in Parkinson's disease.
Summary
ABSTRACTA 78-year-old female with a nine-year history of depression was hospitalized due to worsening depression and symptoms associated with Parkinson's disease (PD). Her motor abilities improved on levodopa and the depression improved after a trial of bupropion, following unsuccessful treatment with other antidepressants. We found four reports on successful treatment of depression in PD with bupropion. However, no controlled double-blind studies have been conducted so clinicians should be cautious when administering bupropion in depression in PD.
Affiliation
IV Department of Psychiatry, Institute of Psychiatry and Neurology, Warsaw, Poland.
Journal Details
Name: International psychogeriatrics / IPA
ISSN: 1741-203X
Pages: 1-3
Links
- PubMed Source: http://www.ncbi.nlm.nih.gov/pubmed/20809995
- DOI: http://dx.doi.org/10.1017/S1041610210001687
MESH Definitions
Anti-dyskinesia Agents
Drugs used in the treatment of movement disorders. Most of these act centrally on dopaminergic or cholinergic systems. Among the most important clinically are those used for the treatment of Parkinson disease (ANTIPARKINSON AGENTS) and those for the tardive dyskinesias.
Isocarboxazid
An MAO inhibitor that is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in the treatment of panic disorder and the phobic disorders. (From AMA, Drug Evaluations Annual, 1994, p311)
Bupropion
A unicyclic, aminoketone antidepressant. The mechanism of its therapeutic actions is not well understood, but it does appear to block dopamine uptake. The hydrochloride is available as an aid to smoking cessation treatment.
Piribedil
A dopamine D2 agonist. It is used in the treatment of parkinson disease, particularly for alleviation of tremor. It has also been used for circulatory disorders and in other applications as a D2 agonist.
Droxidopa
A precursor of noradrenaline that is used in the treatment of parkinsonism. The racemic form (DL-threo-3,4-dihydroxyphenylserine) has also been used, and has been investigated in the treatment of orthostatic hypotension. There is a deficit of noradrenaline as well as of dopamine in Parkinson's disease and it has been proposed that this underlies the sudden transient freezing seen usually in advanced disease. Administration of DL-threo-3,4-dihydroxyphenylserine has been claimed to result in an improvement in this phenomenon but controlled studies have failed to demonstrate improvement. (Reynolds JEF(Ed): Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc, Englewood, CO, 1995)
PubMed Articles 12911 Associated PubMed Articles 
Bupropion as the treatment of choice in depression associated with Parkinson's disease and it's various treatments.
Parkinson disease (PD) is a chronic progressive degenerative disorder that affects over 6million people worldwide. It is manifested by motor and psychiatric signs. The latter inflicts up to 88% of PD...
Bupropion decreases resting motor threshold: A case report.
BACKGROUND: Bupropion is associated with a dose-related increased seizure risk. This effect could correlate with a change in motor cortex excitability. Transcranial magnetic stimulation (TMS) can asse...
A case of bupropion-induced Stevens-Johnson syndrome with acute psoriatic exacerbation.
Bupropion is a very popular medication prescribed to millions of patients globally for depression (Wellbutrin, GlaxoSmithKline, Research Triangle Park, NC) as well as an aid in smoking cessation (Zyba...
Depression in Parkinson's Disease - Part 2: Therapy and Management.
A good number of different methods and antidepressive agents are now available for the management of depressive symptoms, the efficacy of which has been confirmed by clinical studies. Various approach...
Depression in Parkinson disease-epidemiology, mechanisms and management.
Depression occurs in around 35% of patients with Parkinson disease (PD) and is often persistent. Symptoms of depression can be evident in individuals at the time of diagnosis and might develop in the...
Clinical Trials 3738 Associated Clinical Trials 
SAM-e for the Treatment of Depression in Patients With Parkinson's Disease
This study will test a chemical called s-adenosyl-methionine (SAM-e) for the treatment of depression in patients with Parkinson's disease (PD).
Risperidone vs. Bupropion ER Augmentation of SSRIs in Treatment-Resistant Depression
The purpose of this study is to evaluate the comparative effectiveness of Risperdal (risperidone) or bupropion ER (extended release) combined with a SSRI medication and to test the relativ...
Treatment of Depression in Parkinson's Disease Trial
The goal of this study is to evaluate the effectiveness and safety of two antidepressants--nortriptyline and paroxetine, compared to placebo in patients with Parkinson's disease and depre...
Cognitive Behavioral Therapy for Depression in Parkinson's Disease
The purpose of this pilot program is to develop and evaluate a new treatment program for depression in Parkinson's disease (PD). The treatment uses Cognitive Behavior Therapy(CBT)to teach...
Healthcare Utilization and Functional Disability in Parkinson's Disease
Parkinson's Disease (PD) is often thought of as affecting movement only. In fact, more than 40% of patients also have anxiety and/or depression. The goals of this study are: (1) to evalu...
Associated Content for this Article
- View Related News Articles
- View Related Events
- View Related Companies
- View Related Medications
- View Related Channels
Searches Linking to this Page
bupropion and parkinson's, bupropione parkinson, bioportfolio bupropion parkinson, bupropion parkinson motor effect, Bupropion Parkinson, parkinson disease and depression, wellbutrin parkinsonism, Wellbutrin Parkinson, wellbutrin parkinson, parkinson disease bupropion, parkinsonism wellbutrin, bupropion parkinson, parkinson bupropione, parkinson's disease bupropion, Wellbutrin for parkinson's